Identification of Genes Associated with Tumor Suppression in Syrian Hamster Embryo Cells

by Roger W. Wiseman,* Jeffry C. Montgomery,* Junichi Hosoi,* Esther W. Hou,* Charles J. Cochran,* Patricia W. Lamb,* and J. Carl Barrett*

Loss of a tumor-suppressor gene function appears to play a critical role in the multistep process of neoplastic transformation of Syrian hamster embryo (SHE) cells in vitro. Clonal variants of two independent, preneoplastic cell lines have been isolated that have either retained (termed supB+) or lost (termed supB−) the ability to suppress the tumorigenicity of a highly malignant benzo(a)pyrene-transformed SHE cell line (BP6T) in cell hybrids. We have pursued several approaches in an attempt to identify genes that are responsible for tumor suppression in these cells. The only consistent differences detected in two-dimensional gel analyses of supB+ and supB− cellular proteins were decreases in the levels of two high molecular weight isoforms of tropomyosin in supB− cells. Differential screening of a supB+ cDNA library for genes that are preferentially expressed in supB− cells yielded cDNA clones for four genes, i.e., collagen type II, collagen type IX, H19, and a previously unidentified gene (clone 5). Nuclear run-on assays suggested that higher transcription rates were responsible for the increased steady-state levels of some of these transcripts in supB− cells. DNA sequence comparisons showed that two copies of a 9 bp element, previously identified in each of the mouse H19 enhancers, were also present in the 5′ flanking region of the rat type II collagen gene. A transcription factor that controls expression of the collagen and H19 genes through binding to this conserved motif would be an attractive candidate for the supB+ gene or at least a mediator of the supB+ phenotype.

Role of Tumor-Suppressor Genes in Multistep Carcinogenesis

It is now well established that the carcinogenic process requires the accumulation of multiple heritable alterations for the complete malignant transformation of normal cells (1–3). It is also clear that the inactivation of tumor-suppressor genes plays an important role in the genesis of a wide variety of human tumors (3,4). Strong evidence for this concept has been provided by studies of the suppression of tumorigenicity in somatic cell hybrids (5,6), genetic predispositions to cancer (7,8), and nonrandom chromosomal deletions or allelic losses in specific chromosomal regions (9,10). A number of these tumor-suppressor genes have recently been isolated by molecular cloning techniques (11–15), and in several cases tumor-suppressor activity has been demonstrated in functional assays (16–18).

We have previously demonstrated that the loss or inactivation of a tumor-suppressor gene function is a critical event during the neoplastic transformation of carcinogen-treated or oncogene-transfected Syrian hamster embryo cells in vitro (19,20). The conversion of these normal cells to fully malignant tumor cells is clearly a multistep process (Fig. 1). Rare cells in carcinogen-treated cultures escape cellular senescence and form immortal (sen−) cell lines (21,22). These cell lines

![Figure 1](https://example.com/figure1.png)
are preneoplastic and require many population doublings in vitro prior to becoming anchorage independent (SA−) or tumorigenic (tum+) when injected subcutaneously into nude mice. The tumorigenic phenotype is strongly supported in cell hybrids formed between a benzo[a]pyrene-induced tumor cell line (BP6T) and normal SHE cells or early passage preneoplastic lines. At later passages, however, the ability of preneoplastic cell populations to suppress tumorigenicity becomes heterogeneous (19). A series of variants that differ more than 15- to 30-fold in their ability to suppress the tumorigenicity of BP6T cells (Table 1) have been subcloned from two independent preneoplastic lines (DES4 and 10W) (23). These subclones are designated supB+ or supB− since BP6T cells represent only one of at least three different complementation groups for tumor suppression of hamster sarcomas (24). Interestingly, the supB− phenotype co-segregates with the ability to reversibly grow with high cloning efficiencies in soft agar supplemented with tumor cell-conditioned media or a combination of epidermal growth factor, insulin, and platelet-derived growth factor (19, 23).

Identification of Genes Preferentially Expressed in Cells Retaining the Ability to Suppress Tumorigenicity

To isolate candidates for the BP6T tumor-suppressor gene function, we have used two approaches to identify genes that are preferentially expressed in supB+ cells relative to supB− cells. The feasibility of these approaches is enhanced by the fact that the supB+ and supB− cell lines are very closely related, having been subcloned from the same parental lines. In addition, we have used supB+ and supB− variants derived from two independent parental cell lines, i.e., DES4 and 10W (23); this should increase the probability that the alterations we have detected are directly related to the supB+ phenotype rather than simply fortuitous events.

Initially, we examined the levels of more than 1000 [35S]methionine-labeled proteins from total cell lysates of the supB− and supB+ subclones using the Quest system (25) for quantitative two-dimensional gel electrophoresis. These studies were performed in collaboration with Michael Lambert and James Garrels (Cold Spring Harbor Laboratory). Given the sensitivity of this type of analysis, specific protein levels were very similar between the two cell types, as expected for these clonal derivatives. The only consistent alterations that were detected between each of the supB− and supB+ cell lines were reductions of two high molecular weight tropomyosins in supB+ cells (26). These tropomyosin isoforms were identified by comparisons with two-dimensional gel patterns of rat and human proteins as well as by immunoprecipitation with tropomyosin-specific antisera. Tropomyosin 1 and tropomyosin 2 levels were decreased 6-fold and 2-fold, respectively, in supB+ cells relative to supB− cells. Analysis of silver-stained gels revealed similar reductions in the steady-state levels of these proteins in supB− cells. Likewise, comparable decreases in tropomyosin 1 mRNA were observed by Northern analysis with a rat tropomyosin cDNA probe in supB− cells.

Previous studies by several laboratories have reported decreased expression of high molecular weight tropomyosins isoforms in virally and chemically induced tumor cells relative to immortal precursor cells (27–30). However, our observations are the first example of altered tropomyosin expression in cells prior to neoplastic transformation. Stress fiber organization in supB+ and supB− cells was also compared since tropomyosins are cytoskeletal proteins that are thought to stabilize actin microfilaments. Fluorescent microscopy of cells stained with rhodamine-phalloidin demonstrated that the actin stress fibers of supB+ cells were highly organized, while supB− cells consistently exhibited a diffuse, disorganized actin staining pattern common in tumor cells (31; J. Boyd, unpublished results). Studies using antisense techniques are underway to address a possible role for these cytoskeletal alterations in the supB+ phenotype.

The second approach (Fig. 2) that we have adopted to identify genes that are preferentially expressed in supB+ cells is the differential screening of cDNA libraries (31). A series of 31 supB+ specific plaques were isolated by screening a DES4supB+ cell lambda ZAP cDNA library sequentially with 32P-labeled total cDNA probes prepared from DES4supB− and DES4supB+ mRNA. For further analysis, cDNA inserts were excised from the lambda ZAP phage as pSK− phagemid. These cDNA clones represented four different genes based on Northern analyses and cross-hybridization studies.

Northern analysis with two of these cDNAs as probes revealed transcripts of 5.1 kb and 4.5 kb, respectively, that are abundant in supB+ cells but absent or barely detectable in normal SHE cells, supB− cells, and BP6T cells. DNA sequencing revealed that these cDNAs were

| Parental cells | Tumor suppression ratio | Fold suppression | Tumor suppression phenotype |
|---------------|------------------------|-----------------|----------------------------|
| DES4         | 0.90                   | 1.1             | supB−                      |
| DES4         | 1.05                   | 1.0             | supB−                      |
| DES4         | 0.039                  | 25              | supB+                      |
| DES4         | 0.031                  | 25              | supB+                      |
| 10W          | 0.95                   | 1.0             | supB−                      |
| 10W          | 1.11                   | 0.9             | supB−                      |
| 10W          | 1.07                   | 0.9             | supB−                      |
| 10W          | 0.037                  | 27              | supB+                      |
| 10W          | 0.066                  | 15              | supB+                      |

aDES4 (passage 60) and 10W (passage 17) cells were subcloned by one of two methods, i.e., colonies growing in agar supplemented with BP6T tumor cell-conditioned medium (conditionally transformed) or colonies growing in normal medium on plastic tissue culture dishes.

bThe ratio of hybrid colonies formed with BP6T cells that grow in agar to total hybrid colonies formed on plastic.

cTumor suppression ratio. These data were modified from Koi et al. (23) with permission.
Northern analysis with the remaining cDNA (clone 5) revealed a series of transcripts, with major species of 2.5 kb and 3.0 kb as well as several less abundant, larger mRNAs. These transcripts were observed in each of the supB+ and normal SHE cells but were undetectable in the supB− lines and BP6T cells. DNA sequence analysis of over 2 kb at the 3′ end of this cDNA has failed to reveal any significant similarities with sequences currently in the GenBank or European Molecular Biology Laboratory databases.

In an attempt to understand the basis for the coordinate expression of these genes in supB+ and supB− cells, nuclear run-on assays were performed for the collagen and H19 genes. These studies suggested that higher transcription rates were responsible for the increased steady-state levels of these transcripts in supB+ cells. DNA sequence comparisons showed that a 9 bp element, TGT(T/C)TGCGT, that was previously identified in each of the mouse H19 enhancers was also present twice in the 5′ flanking region of the rat type II collagen gene (36,40). Preliminary gel retardation assays revealed the presence of factor(s) in nuclear extracts of supB+ cells that bound to an oligonucleotide containing this conserved motif. Current studies using cDNA expression vector libraries are directed at the isolation of factors that bind to oligonucleotides containing this sequence element.

Conclusions

In this review, we have described two approaches that are directed toward the isolation of the supB+ tumor-suppressor gene. Although the identity of this gene is still unknown, a series of genes whose expression is coordinately regulated with the supB+ phenotype have been identified. If techniques such as differential cDNA screening and two-dimensional protein gel analysis are to succeed, it is essential that the cells being compared are as closely related as possible. The supB+ and supB− cells that we have studied appear to fulfill this criteria. Furthermore, these techniques are based on the hypothesis that the expression of the supB+ tumor-suppressor gene will be absent or greatly decreased in supB− cells. While this assumption is valid for several tumor-suppressor genes that have previously been cloned (11,12), genes like the P53 gene, which is functionally inactivated by point mutations (41), would be missed by these techniques.

The detection of a tumor-suppressor gene product by quantitative two-dimensional gel analysis is limited to moderately abundant proteins that are clearly resolved under the electrophoresis conditions employed. Likewise, isolation of the supB+ gene by differential cDNA screening requires that this gene be expressed as a relatively abundant transcript (> 0.05% of the total mRNA) so that it is represented at a sufficient level in the 32P-labeled probe to yield a detectable hybridization signal (42). However, subtractive hybridization techniques have been used to isolate considerably less abundant transcripts (43,44), and they provide an attractive
extension of the differential cDNA screening studies described in this report. Therefore, our current approach is directed at the construction of a supB + cDNA library after several rounds of subtraction with supB - mRNA. Subtractive hybridization techniques using a mammalian expression vector may also be useful as an enrichment for supB + cDNAs with the potential to suppress the tumorigenicity of BP'Tc cells. Such a subtracted supB + library could be used in gene transfer assays like those described by Noda and co-workers (16) to screen for cDNAs with tumor-suppressing activity.

Of the genes identified whose expression is coordinately regulated with a tumor-suppressor function for BP'Tc cells, two (collagen type II and collagen IX) are differentiation markers, and another (H19) is a developmentally regulated gene. The loss of expression of these differentiation and developmental genes is consistent with the suggestion by Stanbridge and others (5,8) that tumor-suppressor genes may function by inducing differentiation in vivo. Several studies have implicated transcription factors in the control of differentiation, e.g., MyoD in the myogenic differentiation program (44). Since two copies of a 9 bp element, TGT(T/C)TGCA, are conserved between the mouse H19 enhancers and the 5' untranslated region of the rat type II collagen gene, we are currently investigating the existence of a potential transcription factor that binds this sequence and may control the coordinate expression of these genes with the supB + phenotype. Such a transcription factor would be an attractive candidate as a mediator of chondrocyte differentiation and the supB + phenotype, if not the supB + gene itself. This concept is especially intriguing in light of the recent report (45) of a role for the retinoblastoma gene product in transcriptional control of the c-fos promoter.

REFERENCES

1. Weinberg, R. A. Oncogenes, antioncogenes, and the molecular basis of multistep carcinogenesis. Cancer Res. 49: 3713–3721 (1989).
2. Pittot, H. C. Fundamentals of Oncology. Marcel Dekker, New York, 1986, pp. 139–220.
3. Stanbridge, E. J., and Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61: 759–767 (1990).
4. Scrable, H. J., Sapienza, C., and Cavenee, W. K. Genetic and epigenetic losses of heterozygosity in cancer predisposition and progression. Adv. Cancer Res. 54: 25–61 (1990).
5. Harris, H. The analysis of malignancy by cell fusion: the position in 1988. Cancer Res. 48: 3302–3306 (1988).
6. Stanbridge, E. J., Der, C. J., Doesen, C. J., Nishimi, R. Y., Peehl, D. M., Weissman, B. E., and Wilkinson, J. E. Human cell hybrids: analysis of transformation and tumorigenicity. Science 215: 252–259 (1982).
7. Knudson, A. G., Jr. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res. 45: 1437–1443 (1985).
8. Stanbridge, E. J., and Cavenee, W. K. Heritable cancer and tumor suppressor genes: a tentative connection. In: Oncogenes and the Molecular Origins of Cancer, Monograph 18 (R. A. Weinberg, Ed.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989, pp. 281–306.
9. Cavenee, W. K., Dryja, T. P., Phillips, R. A., Benedict, W. F., Goldhout, R., Gailie, B. L., Murphee, A. L., Strong, L. C., and White, R. L. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305: 779–784 (1983).
10. Ponder, B. Gene losses in human tumors. Nature 335: 400–402 (1988).
11. Friend, S. H., Bernards, R., Rogelj, S., Weinberg, R. A., Rapport, J. M., Albert, D. M., and Dryja, T. P. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 329: 643–646 (1988).
12. Fearon, E. R., Cho, K. R., Nigro, J. M., Kerr, S. E., Simons, J. W., Ruppert, J. M., Hamilton, S. R., Preisinger, A. C., Thomas, G., Kinzler, K. W., and Vogelstein, B. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247: 49–56 (1990).
13. Call, K. M., Glaser, T., Ito, C. Y., Buckler, A. J., Pelletier, J., Haber, D. A., Rose, E. A., Kri, A., Yeger, H., Lewis, W. H., Jones, C., and Housman, D. E. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60: 210–220 (1990).
14. Cavithon, R. W., Weiss, R., Xu, G., Wiskochil, D., Culver, M., Stevens, J., Robertson, M., Dunn, D., Gesteland, R., O'Connell, P., and White, R. A. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 63: 192–201 (1990).
15. Wallace, M. R., Marchuk, D. A., Andersen, L. B., Letcher, R., Odeh, H. M., Saulino, A. M., Fountain, J. W., Brereton, A., Nicholson, J., Mitchell, A. L., Brownstein, B. H., and Collins, F. S. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 245: 181–186 (1990).
16. Kitayama, H., Sugimura, Y., Matsuzaki, T., Ikawa, Y., and Noda, M. A ras-related gene with transformation suppressor activity. Cell 56: 77–84 (1989).
17. Huang, H. J. S., Yee, J. K., Shew, J. Y., Chen, P. L., Bookstein, R., Friedman, T., Lee, E. Y. H., and Lee, W. H. Suppression of the neurofibromatosis phenotype by replacement of the RB gene in human cancer cells. Science 242: 1563–1566 (1988).
18. Finlay, C. A., Hinds, P. W., and Levine, A. J. The p53 protooncogene can act as a suppressor of transformation. Cell 57: 1083–1093 (1989).
19. Kol, M., and Barrett, J. C. Loss of tumor-suppressive function due to chromosomal deletions in human hamster embryo cells. Proc. Natl. Acad. Sci. U.S.A. 85: 5992–5996 (1988).
20. Oshimura, M., Kol, M., Ozawa, N., Sugawara, O., Lamb, P. W., and Barrett, J. C. Role of chromosome 18 in ras/myc-induced Syrian hamster tumors. Cancer Res. 48: 1623–1628 (1988).
21. Barrett, J. C., and Ts'o, P. O. P. Evidence for the progressive nature of neoplastic transformation in vitro. Proc. Natl. Acad. Sci. U.S.A. 75: 3781–3785 (1978).
22. Barrett, J. C. A prerequisite stage in the spontaneous neoplastic transformation of Syrian hamster embryo cells in culture. Cancer Res. 40: 91–94 (1980).
23. Kol, M., Afshari, C., Annab, L. A., and Barrett, J. C. Role of a tumor suppressor gene in the negative control of anchorage-independent growth of Syrian hamster cells. Proc. Natl. Acad. Sci. U.S.A. 86: 8773–8777 (1989).
24. Whitehead, R. E., Jr., Sugawara, O., and Barrett, J. C. Multiple tumor suppression activities identified by somatic cell hybridization (abstract). Proc. Am. Assoc. Cancer Res. 29: 456 (1988).
25. Garrels, J. I. The QUEST system for quantitative analysis of two-dimensional gels. J. Biol. Chem. 264: 5289–5292 (1989).
26. Wiseman, R. W., Lambert, M. E., Lamb, P. W., Garrels, J. I., and Barrett, J. C. Alterations in the gene expression at various stages of neoplastic transformation of Syrian hamster embryo (HE) cells (abstract). J. Cell. Biochem. 12A: D325 (1989).
27. Hendricks, M., and Weintraub, H. Tropomyosin is decreased in transformed cells. Proc. Natl. Acad. Sci. U.S.A. 78: 5638–5673 (1981).
28. Matsumura, F., Lin, J. C., Yamashiro-Matsumura, S., Thomas, G. P., and Topp, W. C. Differential expression of tropomyosin forms in the microfilaments isolated from normal and transformed rat cultured cells. J. Biol. Chem. 255: 2937–2943 (1980).
29. Cooper, H. L., Feuerstein, N., Noda, M., and Bassin, R. H. Suppression of tropomyosin synthesis, a common biochemical feature...
tions of oncogenesis by structurally diverse retroviral oncogenes. Mol. Cell. Biol. 5: 972–983 (1985).

30. Garrels, J. I., and Franz, B. R., Jr. Transformation-sensitive and growth-related changes of protein synthesis in REF52 cells. J. Biol. Chem. 264: 5299–5312 (1989).

31. Barrett, J. C., Boyd, J. A., Afshari, C. A., Annab, L. A., Hosoi, J., Montgomery, J. C., Wiseman, R. W., Oshimura, M., and Koi, M. Tumor suppressor genes as negative regulators of cell growth. In: Current Communications in Molecular Biology: Recessive Oncogenes and Tumor Suppression (W. K. Cavenee, N. D. Hastie, and E. J. Stanbridge, Eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989, pp. 11–17.

32. Barrett, J. C., Boyd, J. A., Afshari, C. A., Annab, L. A., Hosoi, J., Montgomery, J. C., Wiseman, R. W., Oshimura, M., and Koi, M. The product of the H19 gene may function as an RNA. Mol. Cell. Biol. 10: 28–36 (1990).

33. Scott, M. R. D., Westphal, K. H., and Righy, P. W. J. Activation of mouse genes in transformed cells. Cell 30: 481–490 (1982).

34. Lukens, L., Frischauf, A., Pawlowski, P., Brierley, G., and Leh- rach, H. Construction and characterization of type II collagen complementary DNA clones. Nucleic Acids Res. 11: 6921–6939 (1983).

35. Cheah, K. S. E., Stoker, N. G., Griffin, J. R., Grosveld, F. G., and Solomon, E. Identification and characterization of the human type II collagen gene (COL2A1). Proc. Natl. Acad. Sci. U.S.A. 82: 2555–2559 (1985).

36. Kimura, T., Mattei, M., Stevens, J., Goldring, M., Ninomiya, Y., and Olsen, B. Molecular cloning of rat and human type IX collagen cDNA and localization of the alpha1(IX) gene on the human chromosome 6. Eur. J. Biochem. 179: 71–78 (1989).

37. Mendler, M., Eich-Bender, S. G., Vaughan, L., Winterhalter, K. H., and Bruckner, P. Cartilage contains mixed fibrils of collagen types II, IX, and XI. J. Cell Biol. 108: 191–197 (1989).

38. Pachnis, V., Brannan, C. I., and Tilghman, S. M. The structure and expression of a novel gene activated in early mouse embryogenesis. EMBO J. 7: 673–681 (1988).

39. Brannan, C. I., Dees, E. C., Ingram, R. S., and Tilghman, S. M. Two regulatory domains flank the mouse H19 gene. Mol. Cell. Biol. 8: 4707–4715 (1988).

40. Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup J. M., van Tuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., White, R., and Vogelstein, B. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244: 217–221 (1989).

41. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

42. Hendrick, S. M., Cohen, D. I., Nielsen, E. A., and Davis, M. M. Isolation of cDNA clones encoding T cell-specific membrane-associated proteins. Nature 308: 149–153 (1984).

43. Davis, R. L., Weintraub, H., and Lassar, A. B. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 51: 987–1000 (1987).

44. Robbins, P. D., Horowitz, J. M., and Mulligan, R. C. Negative regulation of human c-fos expression by the retinoblastoma gene product. Nature 346: 668–671 (1990).